MUHC launches FEEL‑CUSM trial of Paxman scalp‑cooling system to reduce chemo hair loss
The McGill University Health Centre is running FEEL‑CUSM to evaluate the Paxman scalp‑cooling system for chemotherapy patients. Four devices are on one‑year loan; the team aims to recruit 100 participants aged 18–40 and hopes to deliver data within a year to support public funding.
Oncologists at the Cedars Cancer Centre (MUHC) have started the FEEL‑CUSM clinical trial to assess Paxman, a scalp‑cooling device described as more affordable and user‑friendly than prior systems. The MUHC currently has four units provided on a one‑year loan by the manufacturer. The trial seeks 100 patients aged 18–40 to evaluate effects on hair preservation, patient comfort and anxiety during chemotherapy, with the objective of producing evidence to inform potential public coverage.
Read the original story · Le Canada Francais — https://www.canadafrancais.com/nouvelles-nationales/chimio-le-cusm-met-a-lessai-un-nouveau-dispositif-contre-la-perte-de-cheveux/